BIOSIG TECHNOLOGIES (OTCMKTS:BSGM)’s Trend Up, Especially After Decreased Shorts

September 17, 2017 - By Peter Erickson

The stock of BIOSIG TECHNOLOGIES (OTCMKTS:BSGM) registered a decrease of 3.74% in short interest. BSGM’s total short interest was 18,000 shares in September as published by FINRA. Its down 3.74% from 18,700 shares, reported previously. With 31,700 shares average volume, it will take short sellers 1 days to cover their BSGM’s short positions.

The stock increased 1.10% or $0.01 on September 15, reaching $1.26. About 1,959 shares traded. BioSig Technologies Inc (OTCMKTS:BSGM) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

BioSig Technologies, Inc. is a development-stage medical device company. The company has market cap of $32.77 million. The Firm is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It currently has negative earnings. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms electro-pneumatic (EP) System.

More notable recent BioSig Technologies Inc (OTCMKTS:BSGM) news were published by: Tcbmag.com which released: “BioSig Technologies Issues Big Warrant Position to Mayo Clinic Ventures” on May 31, 2017, also Globenewswire.com with their article: “BioSig Technologies Sponsors The 11th International Symposium on Ventricular …” published on September 26, 2016, Marketwired.com published: “BioSig Technologies Announces the Appointment of Jerome B. Zeldis to Its Board …” on April 09, 2015. More interesting news about BioSig Technologies Inc (OTCMKTS:BSGM) were released by: Globenewswire.com and their article: “BioSig Technologies Provides Shareholder Update” published on April 25, 2017 as well as Globenewswire.com‘s news article titled: “BioSig Technologies to Present at SeeThruEquity 3rd Annual Innovations …” with publication date: February 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: